Holen Sie sich die Stockscreener-App
1.38
8.66%
0.11
Vorhandelsmarkt:
1.35
-0.03
-2.17%
Schlusskurs vom Vortag:
$1.27
Offen:
$1.25
24-Stunden-Volumen:
136.75K
Relative Volume:
0.03
Marktkapitalisierung:
$3.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-0.2663
EPS:
-5.1824
Netto-Cashflow:
$-18.40M
1W Leistung:
-15.34%
1M Leistung:
+1,061%
6M Leistung:
+88.60%
1J Leistung:
-54.00%
1-Tages-Spanne:
$1.25
$1.46
1-Wochen-Bereich:
$1.25
$1.63
52-Wochen-Spanne:
$0.095
$1.93
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Firmenname
Calidi Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 794-9600
Adresse
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.38 | 3.11M | 0 | -25.09M | -18.40M | -5.1824 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-09 | Eingeleitet | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
Calidi Biotherapeutics (CLDI) grants director 5,000 options - Stock Titan
Calidi director granted 4,000 options at $1.36 | CLDI Insider Trading - Stock Titan
Calidi Biotherapeutics (CLDI) gives CFO 14,000 options with 10-year term - Stock Titan
Calidi Biotherapeutics (CLDI) awards director 4,000 options vesting in 1 year - Stock Titan
Calidi Biotherapeutics (CLDI) grants director 6,000 options vesting in 12 months - Stock Titan
Calidi (CLDI) Closing Snapshot: Retreats 5.59% to $1.28 in the Current Update; Technical Position: the Near-Term Reference Band Stretches From $1.22 to $1.34 on the DayCalendar Spread Trade - Vinanet
Armistice Capital reports 4.99% Calidi Biotherapeutics (CLDI) stake in Schedule 13G/A - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 8K Calidi Biotherapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress - TipRanks
Calidi Biotherapeutics Q2 net loss narrows to $4.2M; G&A cuts 48% - scanx.trade
Calidi Biotherapeutics 2Q 2026: Net loss $4.16M, EPS $(2.94) — 10-Q Summary - TradingView
Calidi Biotherapeutics Reports Positive FDA Pre-IND Feedback for CLD-401, Showcases RedTail Platform Data and Cuts G&A Expenses - Quiver Quantitative
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Price to book forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Price to sales forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Calidi Biotherapeutics (CLDI) Holds Steady at $1.63 as Stock Sits Between Support and ResistanceStock Surge Alerts - Vinanet
CLDI Q4 2025 Earnings: Narrower Loss of -$0.43 Per Share Beats Estimates, Stock Falls 9.5%High Estimate Range - Vinanet
Calidi Biotherapeutics (CLDI) Insider Trading Activity 2026 $CLDI - MarketBeat
Calidi Biotherapeutics (CLDI) Jumps 12.5% to $1.89 as Bullish Momentum Builds Toward $1.98 ResistanceSector Neutral Pair - Vinanet
Price to sales forward of Calidi Biotherapeutics, Inc. – BOATS:CLDI - TradingView
Calidi Biotherapeutics Inc. (NYSE: CLDI) Share Price, CLDI Stock News, CLDI Share Price & Updates - Kalkine
Calidi Biotherapeutics Announces Reverse Stock Split to Maintain NYSE American Listing – July 2026 8-K Filing - Minichart
Calidi Biotherapeutics Implements Reverse Stock Split on NYSE - TipRanks
Calidi Biotherapeutics Inc (CLDI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLDI|Calidi Biotherapeutics Inc|Price:0.109|Chg%:+0.009 - TradingKey
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference - GlobeNewswire
Calidi Biotherapeutics Inc (CLDI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Calidi highlights new EpCam-targeting T-cell engager data - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Calidi Biotherapeutics Inc (CLDI) Cash Flow - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
TradingKey - TradingKey
CLDI Q4 2025 Earnings: Smaller-Than-Expected Loss Fails to Lift SharesGrowth Acceleration Report - Vinanet
Calidi Biotherapeutics Inc (CLDI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics To Carry Out 1-for-16 Reverse Stock Split On July 31st, 2026 - Moomoo
Calidi Gains on Company Update - Baystreet.ca
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - The Manila Times
Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split - marketscreener.com
Calidi Announces Reverse Stk Split, Expected to Begin Trading on a 1-For-16 Split Adjusted Basis on July 31 - Moomoo
Calidi shareholders will get one share for every 16 held - Stock Titan
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - Yahoo Finance
CLDI Q4 2025 Earnings: EPS Beats Estimates by 73.6% as Company Advances Clinical PipelineOperating Income Trends - Vinanet
Calidi Biotherapeutics Plans Relocation Through New Lease Agreements - TipRanks
Calidi Biotherapeutics Signs 44-Month Lease at 5580 Morehouse Drive, San Diego for New Corporate Headquarters - Minichart
New lease could save Calidi Biotherapeutics (NYSE American: CLDI) $1.1M yearly - Stock Titan
CLDI Q4 2025 Earnings: EPS Beat by 73.59% Despite No RevenueEarnings Season Outlook - Vinanet
Calidi Biotherapeutics (CLDI) Slides Over 8% as Stock Nears Critical Support Level at $0.11Breakout Trade - Vinanet
Calidi Biotherapeutics grants inducement options to new VP Finance - scanx.trade
Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.42%
0.62%
Kapitalisierung:
|
Volumen (24h):